Home » Focus Areas » Life Sciences and Biotechnology

Life Sciences and Biotechnology

“The scientific community and the FDA believe it is critical to identify and study patients with very early Alzheimer’s disease before there is too much irreversible injury to the brain. It is in this population that most researchers believe new drugs have the best chance of
providing meaningful benefit to patients.”

                – Russell Katz, MD, Director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research

Abeta 2lfm.jpg

Amyloid beta peptide

The Life Sciences and Biotechnology group at SoSACorp is focused on the development of a simple, accurate and cost-effective blood-based diagnostic that will create the ability to test asymptomatic people for Alzheimer’s disease—before they have the signs of the disease.

SoSACorp has a strong intellectual property position including a core technology patent issued in 2007 that describes a method for detecting misfolded proteinaceous particles comprised of predominantly beta‐sheet secondary structure. In addition, our portfolio contains over 10 patent family applications (most of which were also filed at the National stage) with 30 issued patents (5 in the US) and 5 patent family applications pending that include claims for the diagnosis of folded protein diseases, therapeutic screening and therapeutic activity. SoSACorps patents include:

Pronucleon™Pronucleon

SoSACorp holds a trademark on the term Pronucleon™ to describe the manner and method by which our peptide technology works.

Pronucleon™ is a platform technology using custom-synthesized peptides that allow signal amplification to map the surface of rare proteins. Unlike our platform, recognition molecules used in currently available diagnostic assays for amyloid proteins (e.g. antibodies, aptamers) are not particularly sensitive to protein conformational state.

We have created peptides specific for detection of oligomer and fibrillar forms of Aβ.earlydetection

Platform Technology for Determining Protein Conformation

Using unique technology that detects both the sequence and the conformation of amyloid proteins, our goal is to create sensitive and specific detection methods that allow early stage diagnosis and disease progression monitoring.

Related Scientific ArticlesNeurons

  • In Vivo and Ex Vivo Imaging of Amyloid-beta Cascade Aggregates with a Pronucleon™ Peptide
    Journal of Alzheimers Disease – Go to abstract
  • Structure-selective Anisotropy Assay for Amyloid Beta Oligomers
    ACS Chemical Neuroscience Journal – Go to abstract
  • Emerging Principles and Biomarkers in In Vitro Diagnostics for Alzheimer’s Disease
    Chapter 2 in “Alzheimer’s Disease: Targets for New Clinical Diagnostic & Therapeutic Strategies”
    Editors A.S. Rudolph and R. D. Wegrzyn
  • Imaging Biomarkers for Diagnosis, Prognosis, and Treatment of Alzheimer’s Disease
    Chapter 3 in “Alzheimer’s Disease: Targets for New Clinical Diagnostic & Therapeutic Strategies”
    Editors A.S. Rudolph and R. D. Wegrzyn
  • Detection of misfolded prion protein in blood with conformationally sensitive peptides
    Transfusion Journal – Go to abstract
  • Rapid presymptomatic detection of PrPSc via conformationally responsive palindromic PrP
    peptides

    Peptides – Go to abstract